Abstract: The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of proteins expressed in host cells.

Abstract: The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of recombinant proteins expressed in host cells.

Abstract: The present invention relates to the field of protein production and, in particular, to methods and compositions for modulating the glycosylation of recombinant proteins expressed in host cells using cell culture media supplemented with cobalt.

Abstract: The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of proteins expressed in host cells.

Abstract: The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of proteins expressed in host cells.

Abstract: Supplementation of the bioflavonoids such as epigallocatechin gallate, rutin, naringin, or genistein into mammalian cell culture media are shown to be effective in reduction of acidic species variants on recombinant antibodies. The demonstrated reduction in acidic species through the use of bioflavonoids, facilitates the manufacturing of a less heterogeneous product with potential improvements in antibody structure and function.

Abstract: The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of recombinant proteins expressed in host cells.

Abstract: The present invention relates to methods of selecting and developing a chemically defined media (“CDM”) for use in the manufacture of biological products. In particular, the present invention is directed to screening methods to determine cell culture technique media supplement blends with enhanced performance characteristics. The present invention is also directed to identifying CDM supplement blends that demonstrate significant increases in harvest titer and/or viable cell density.

Abstract: Supplementation of the bioflavonoids such as epigallocatechin gallate, rutin, naringin, or genistein into mammalian cell culture media are shown to be effective in reduction of acidic species variants on recombinant antibodies. The demonstrated reduction in acidic species through the use of bioflavonoids, facilitates the manufacturing of a less heterogeneous product with potential improvements in antibody structure and function.

Abstract: The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of proteins expressed in host cells.

Abstract: The present invention relates to methods of selecting and developing a chemically defined media (“CDM”) for use in the manufacture of biological products. In particular, the present invention is directed to screening methods to determine cell culture technique media supplement blends with enhanced performance characteristics. The present invention is also directed to identifying CDM supplement blends that demonstrate significant increases in harvest titer and/or viable cell density.

Abstract: A method and apparatus for managing dependencies in a distributed environment to ensure the safety of remote procedure calls is disclosed. Each remote procedure call between a calling procedure and a target procedure includes an expected time stamp and expected signature associated with the target procedure. The expected time stamp contains the creation time of the target procedure at the time the calling procedure was last compiled. The expected signature contains data type information of the target procedure formal parameters at the time the calling procedure was last compiled. The target procedure compares the expected time stamp to an actual time stamp maintained by the target procedure. If the two time stamps do not match, the target procedure compares the expected signature and an actual signature maintained by the target procedure to determine whether the data types of the formal parameters sent by the calling procedure are compatible with the data types expected by the target procedure.